Aurinia PharmaceuticalsvsJohnson & Johnson

AUPH and JNJ stock compared: price, dividend, valuation and results, from SEC filings.

AUPH

Aurinia Pharmaceuticals Inc

$15.13

Value $2.0B

-1.75%
AUPH's page

Aurinia Pharmaceuticals (AUPH) has a market value of $2.0B and Johnson & Johnson (JNJ) $657B. Over the last year, with dividends, AUPH moved -2.3% and JNJ +39.7%. Dividend yield: AUPH none, JNJ 1.94%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    AUPH$2.0B

    JNJ$657B

    JNJ is 327 times AUPH

  • Revenue, 12 months

    AUPH$322M

    JNJ$99.3B

    JNJ is 309 times AUPH

  • Net income, 12 months

    AUPH$314M

    JNJ$16.1B

    JNJ is 51 times AUPH

  • Operating margin

    AUPH48.6%

    JNJ–

  • ROIC

    AUPH22.2%

    JNJ12.4%

    9.8 points apart

  • P/E

    AUPH–

    JNJ40.8

  • Dividend yield

    AUPH0.0%

    JNJ1.9%

    1.9 points apart

  • 5-year return

    AUPH-48.2%

    JNJ+92.0%

    140.2 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

AUPH-48.2%

JNJ+92.0%

10020020222023202420252026
Returns by period
PeriodAUPHWith dividendsJNJWith dividends
1 year since November 17, 2025-2.3%Price -2.3%+39.7%Price +36.6%
3 years since November 17, 2023+75.9%+20.7% a yearPrice +75.9%+98.2%+25.6% a yearPrice +82.1%
5 years since November 17, 2021-48.2%-12.3% a yearPrice -48.2%+92.0%+13.9% a yearPrice +67.0%
10 years since November 18, 2016+315.7%+15.3% a yearPrice +315.7%+208.0%+11.9% a yearPrice +136.4%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

AUPHAurinia PharmaceuticalsJNJJohnson & Johnson

Valuation

AUPHJNJ
Valuation
Price$15.13$272.70
Market value$2.0B$657B
Enterprise value (EV)$1.6B$685B
P/E–40.8
P/E, 5-year median–21.9
P/B3.18.1
EV/EBIT10.138.6
Free cash flow yield8.8%3.1%

Results and growth

AUPHJNJ
Results and growth
Revenue, 12 months$322M$99.3B
Net income, 12 months$314M$16.1B
Free cash flow, 12 months$177M$20.6B
Earnings per share, 12 months$2.29$6.59
Revenue growth, year on year20.4%6.1%
Revenue growth a year, past+41.4%over 5 years+2.7%over 5 years
EPS growth a year, past–+14.9%over 5 years

Margins and returns on capital

AUPHJNJ
Margins and returns on capital
Gross margin90.6%67.6%
Operating margin48.6%–
Net margin97.7%16.2%
ROIC22.2%12.4%
ROE56.4%19.7%

Balance sheet

AUPHJNJ
Balance sheet
Cash$487M$17.2B
Total debt$59M$44.7B
Net debt / EBITDA-2.51.1
Interest cover40.4×18.0×

Dividends and buybacks

AUPHJNJ
Dividends and buybacks
Dividend yield–1.9%
Dividend per share, 12 months–$5.28
Dividend growth a year, past–+5.3%over 5 years
Buyback yield4.9%0.9%
Shareholder yield4.9%2.9%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: AUPH or JNJ

Didn't find what you were looking for?

Ask us
Which is bigger, Aurinia Pharmaceuticals or Johnson & Johnson?

By market value, Johnson & Johnson ($657B) is about 326.7 times Aurinia Pharmaceuticals ($2.0B), at today's prices.

How did AUPH and JNJ stock do over the last 10 years?

Since November 18, 2016, AUPH's price moved +315.7% and JNJ's +136.4%. With dividends: AUPH +315.7% (+15.3% a year), JNJ +208.0% (+11.9% a year). Past returns do not predict future ones.

Which pays the higher dividend, AUPH or JNJ?

The dividend yield at today's price is none for Aurinia Pharmaceuticals and 1.94% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.

Which has the higher profit margins, Aurinia Pharmaceuticals or Johnson & Johnson?

Over the last twelve months, the net margin was 97.7% for Aurinia Pharmaceuticals and 16.2% for Johnson & Johnson, and the operating margin 48.6% and –. Revenue was $322M and $99.3B.

Which is the better investment, Aurinia Pharmaceuticals or Johnson & Johnson?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.